The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Open accessAbstract
BACKGROUND: Higher intake of marine n-3 (also called omega-3) fatty acids has been associated with reduced risks of cardiovascular disease and cancer in several observational studies. Whether supplementation with n-3 fatty acids has such effects in general populations at usual risk for these end points is unclear. METHODS: (at a dose of 2000 IU per day) and marine n-3 fatty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States. Primary end points were major cardiovascular events (a composite of myocardial infarction, stroke, or death from cardiovascular causes) and invasive cancer of any type. Secondary end points included individual components of the composite cardiovascular end point, the composite end point plus coronary revascularization (expanded composite of cardiovascular events), site-specific cancers, and death from cancer. Safety was also assessed. This article reports the results of the comparison of n-3 fatty acids with placebo. RESULTS: A total of 25,871 participants, including 5106 black participants, underwent randomization. During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24). Invasive cancer was diagnosed in 820 participants in the n-3 group and in 797 in the placebo group (hazard ratio, 1.03; 95% CI, 0.93 to 1.13; P=0.56). In the analyses of key secondary end points, the hazard ratios were as follows: for the expanded composite end point of cardiovascular events, 0.93 (95% CI, 0.82 to 1.04); for total myocardial infarction, 0.72 (95% CI, 0.59 to 0.90); for total stroke, 1.04 (95% CI, 0.83 to 1.31); for death from cardiovascular causes, 0.96 (95% CI, 0.76 to 1.21); and for death from cancer (341 deaths from cancer), 0.97 (95% CI, 0.79 to 1.20). In the analysis of death from any cause (978 deaths overall), the hazard ratio was 1.02 (95% CI, 0.90 to 1.15). No excess risks of bleeding or other serious adverse events were observed. CONCLUSIONS: Supplementation with n-3 fatty acids did not result in a lower incidence of major cardiovascular events or cancer than placebo. (Funded by the National Institutes of Health and others; VITAL ClinicalTrials.gov number, NCT01169259 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“although only REDUCE-IT has shown cardiovascular benefits (as discussed later) (14-17).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“butseverallargeclinicaltrialsfailed to demonstrate any cardiovascular benefit with administration of low doses of omega-3 fatty acids. 8,12,13”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TheVitaminDandOmega-3Trial(VITAL), in which 13% of the participants had type 2 diabetes, supplementation with 1 g of omega-3 fatty acids did not result in a lower incidence of major cardiovascular events (305).”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [305]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials revealed that ω3 PUFA supplementation of <1 g/d resulted in a very limited reduction in atherosclerotic CVD risk of major vascular events and CVD‐caused deaths. 22 , 23 , 133 , 154”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [23]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies showed inconsistent reductions in MACE.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple large studies conducted since then to examine the benefits of low-dose mixtures of EPA and DHA with more contemporary background therapy, including statin therapy, have failed to show any significant reduction in cardiovascular endpoints.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, other recent trials studying lower doses of omega-3 fatty acids in a broader range of patients failed to demonstrate significant reductions of total cardiovascular events. 12,13”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“This may explain why EPA + DHA combination treatment in various trials did not demonstrate an effect on reducing cardiovascular risk. 23 , 24 , 25 , 133”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Earlier trials such as GISSI-Prevenzione, ASCEND, VITAL, and OMEMI evaluated low-dose EPA/DHA mixtures primarily in primary prevention settings or post-MI patients, often without significant baseline TG elevation and with limited use of statins in earlier trials [87–90].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ASCEND (A Study of Cardiovascular Events in Diabetes) [3] and VITAL (Vitamin D and Omega-3 Trial) trials [5] using EPA+DHA did not signi fi cantly reduce the primary cardiovascular endpoints”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“During a median follow-up of 5.3 years, there was no significant difference in the 2 primary endpoints of major cardiovascular events (a composite of MI, stroke, or death from cardiovascular causes) or invasive cancer of any type.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
In the citing paper
“Contemporary studies were conducted with higher standards and consistently failed to demonstrate significant benefits.”
In the citing paper
“at lower doses (1 g/day) these agents have generally failed to show reduced ASCVD.50,51”
From Clinical review on triglycerides (2020) · cites this paper as [51]
In the citing paper
“Recently, a new selective PPAR-α modulator (pemafibrate) has been reported to have marked efficacy in reducing TRLs [317].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [317]
In the citing paper
“However, this trial showed that just 840 mg of combined EPA/DHA significantly reduced MI and major CHD events [63].”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [63]
In the citing paper
“This study did not show that supplementing with n-3 fatty acids reduced the incidence of major CVD events (a composite of MI, stroke, and death from CVD causes) or invasive cancer.”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [63]
In the citing paper
“Individuals with low baseline fish consumption (<1.5 servings/week) had decreased risk for total CV events (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.67 to 0.98).”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“However, there was a 28% reduction in total MI, which emerged after the first year and continued throughout the trial.”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“In the VITAL trial, omega-3 PUFAs did not significantly reduce the primary composite endpoint of major ASCVD events (MI, stroke, and CVD mortality).”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“Black study participants experienced a 77% treatment-associated reduction in MI (HR: 0.23; 95% CI: 0.11 to 0.47), and derived an MI benefit irrespective of baseline fish intake.”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“There were significant reductions in other pre-specified secondary outcomes, including a 17% reduced risk for total coronary heart disease (CHD) and a 50% reduction in fatal MI”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“In the statin era, CVOTs of combination OM-3 fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] have not shown reduction in cardiovascular disease (CVD) events.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“Additional factors that may influence CVOT findings include OM-3 dose, definition of primary composite CV endpoint, and study population.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“The total daily dose of OM-3 was much lower in VITAL and ASCEND (< 1 g/day total OM-3 per each 1-g capsule) than in REDUCE-IT (4 g/day high-purity Rx EPA).”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“The primary composite CV endpoint varied between the studies (Table 1, see footnote); for example, in REDUCE-IT, coronary revascularization and unstable angina were included, in addition to CV death, nonfatal myocardial infarction, and nonfatal stroke.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“A 17% risk reduction was recorded for total coronary heart disease, versus placebo.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“Indeed, while the primary outcome of the study, a reduction in major cardiovascular events (a composite of myocardial infarction, stroke, and death from cardiovascular causes), was not achieved with statistical significance, the analysis did demonstrate an 8% reduction in such events.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“Interestingly for African-Americans, the study found a dramatic 77% reduction in heart attacks linked to daily omega-3 supplementation.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“In people who do not consume the recommended 1 or 2 servings of fish a week, the n-3 LCPUFA supplementation was linked to a 40% reduction in heart attacks; however, among the subjects who followed the fish consumption recommendation, there was no such association.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“The primary conclusion of the VITAL study was not positive regarding the effect of supplementation with n-3 LCPUFA on major cardiovascular events as the data failed to show a lower incidence of major cardiovascular events in the experimental group than in the placebo control group [53].”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“However, the secondary outcomes were highly relevant as omega-3 supplementation was associated with a reduction in total and fatal myocardial infarction risk by 28% and 50%, respectively.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,350
Self-citationPrevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
Third universal definition of myocardial infarction
the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., CHAITMAN, B. R., & White, H. D. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.122 · Cited by 6,585
Isolated Hand Paresis: A Case Series
Alstadhaug, K. B., & Sjulstad, A. S. (2013) · Cerebrovascular Diseases Extra · doi:10.1159/000350708 · Cited by 4,090
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 984
Sherratt, S. C. R., Dawoud, H., Bhatt, D. L., Maliñski, T., & Mason, R. P. (2021) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2021.102337 · Cited by 52
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis
Peng, X., & Wu, H. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01006-w · Cited by 51
Barrea, L., Vetrani, C., Verde, L., Frías-Toral, E., Ceriani, F., Cernea, S., Docimo, A., Graziadio, C., Tripathy, D., Savastano, S., et al. (2023) · Antioxidants · doi:10.3390/antiox12040904 · Cited by 61
“Similar findings were reported in the VITAL trial (in which 13% of the 25,871 participants were patients with T2DM), as the supplementation with 1 g of omega-3 PUFAs did not decrease the frequency of major cardiovascular outcomes [157].”
ResultSerini, S., Cassano, R., Trombino, S., & Calviello, G. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s197499 · Cited by 49
“more recently by the large VITAL study having a 5-year median follow-up confirmed these findings.(119) In this study,”
MethodDarwesh, A. M., Sosnowski, D. K., Lee, T. Y., Keshavarz-Bahaghighat, H., & Seubert, J. M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.037 · Cited by 51
Hypertriglyceridemia: new approaches in management and treatment
Wolska, A. T., Yang, Z., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000710 · Cited by 53
Multi-targeted therapy of cancer by omega-3 fatty acids-an update
Wei, L., Wu, Z., & Chen, Y. Q. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.023 · Cited by 48
Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy
Nakamura, M. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.12568 · Cited by 53
Hilleman, D. E., Wiggins, B. S., & Bottorff, M. B. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01211-1 · Cited by 46
Late-Life Depression: A Narrative Review on Risk Factors and Prevention
Vyas, C. M., & Okereke, O. I. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000240 · Cited by 51
Effect of Vitamin D and ω-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration
Christen, W. G., Cook, N. R., Manson, J. E., Buring, J. E., Chasman, D. I., Lee, I.-M. M., Bubes, V. Y., Li, C., Haubourg, M., & Schaumberg, D. A. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.4409 · Cited by 49
Self-citationSeafood and health: What you need to know?
Liu, C., & Ralston, N. V. C. (2021) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2021.04.001 · Cited by 53
Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022937 · Cited by 47
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Moon, J. H., Kim, K., & Choi, S. H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.402 · Cited by 53
Yan, J. R., Liu, M., Yang, D., Zhang, Y., & An, F. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07379-z · Cited by 50
Huang, L., Zhang, F., Xu, P., Zhou, Y., Liu, Y., Zhang, H., Tan, X., Ge, X., Xu, Y., Guo, M., et al. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.04.009 · Cited by 48
The Effects of Omega 3 and Omega 6 Fatty Acids on Glucose Metabolism: An Updated Review
Egalini, F., Guardamagna, O., Gaggero, G., Varaldo, E., Giannone, B., Beccuti, G., Benso, A. S., & Broglio, F. (2023) · Nutrients · doi:10.3390/nu15122672 · Cited by 51
Li, P., Huang, J., Xiao, N., Cai, X., Yang, Y., Deng, J., Zhang, L., & Du, B. (2020) · Food & Function · doi:10.1039/d0fo01178a · Cited by 49
Tułowiecka, N., Kotlęga, D., Prowans, P., & Szczuko, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207628 · Cited by 45
“The supplement tion with EPA a d DHA or omega-3 fatty acids in th amount of 1 g per day does not significantly reduce the overall a d cardiovascular morbidity of patients with c r iovascular risk factors [73,74].”
BackgroundO’Connell, T. D., Mason, R. P., Budoff, M. J., Návar, A. M., & Shearer, G. C. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa115 · Cited by 45
Bétrisey, S., Haller, M. L., Efthimiou, O., Speierer, A., Giovane, C. D., Moutzouri, E., Blum, M. R., Aujesky, D., Rodondi, N., & Gencer, B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030714 · Cited by 48
Vyas, C. M., Ogata, S., Reynolds, C. F., Mischoulon, D., Chang, G., Cook, N. R., Manson, J. E., Crous‐Bou, M., Vivo, I. D., & Okereke, O. I. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237235 · Cited by 44
Self-citationGabbs, M., Zahradka, P. C., Taylor, C. G., & Aukema, H. M. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa294 · Cited by 42
Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes
Penson, P. E., & Banach, M. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.015 · Cited by 42
Watanabe, Y., & Tatsuno, I. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1863784 · Cited by 43
Mason, R. P., & Eckel, R. H. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.03.014 · Cited by 43
Yang, T., Yi, J., He, Y., Zhang, J., Li, X., Ke, S., Xia, L., & Liu, L. (2022) · Nutrients · doi:10.3390/nu14173608 · Cited by 42
“Moreover, a multicenter prospective cohort also revealed that the circulating levels of ω-3 PUFA (including DHA, EPA, and DPA) were inversely associated with all-cause mortality, especially the CHD death in older adults [36].”
BackgroundNishizaki, Y., Miyauchi, K., Iwata, H., Inoue, T., Hirayama, A., Kimura, K., Ozaki, Y., Murohara, T., Ueshima, K., Kuwabara, Y., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2022.11.008 · Cited by 40
Cheng, C., Yu, X. L., Geng, F., Wang, L., Yang, J., Huang, F., & Deng, Q. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c05335 · Cited by 41
Dietary Composition and Cardiovascular Risk: A Mediator or a Bystander?
Korakas, E., Dimitriadis, G., Raptis, A. E., & Lambadiari, V. (2018) · Nutrients · doi:10.3390/nu10121912 · Cited by 48
“[78] Fatty acids also intervene with inflammation markers which provoke oxidative stress.”
BackgroundSherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P. (2022) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2022.102450 · Cited by 49
Chong, S. Y., Wang, X., van Bloois, L., Huang, C., Sayed, N., Zhang, S., Ting, H. J., Nair, V., Lin, Y., Lou, C. K. L., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.035 · Cited by 46
Severe hypertriglyceridemia: Existing and emerging therapies
Malick, W. A., Do, R., & Rosenson, R. S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108544 · Cited by 45
Costenbader, K. H., Cook, N. R., Lee, I.-M. M., Hahn, J., Walter, J. N., Bubes, V. Y., Kotler, G., Yang, N., Friedman, S., Alexander, E. K., et al. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42811 · Cited by 43
“Characteristics of these participants at the start of the two-year observational follow-up are shown in Table 1 (more details of the initially randomized VITAL participants are published 20,21 ).”
BackgroundSelf-citationBashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy
Kim, A. S., & Conte, M. S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.011 · Cited by 42
Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events
Sharma, G. V., Martin, S. S., & Blumenthal, R. S. (2020) · JAMA · doi:10.1001/jama.2020.22387 · Cited by 42
Omega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials
Jia, X., Kohli, P., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0763-0 · Cited by 39
Kumar, M., Orkaby, A. R., Tighe, C. A., Villareal, D. T., Billingsley, H., Nanna, M. G., Kwak, M. J., Rohant, N., Patel, S., Goyal, P., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100560 · Cited by 46
Strategies to Overcome Residual Risk During Statins Era
Cho, K. I., Yu, J., Hayashi, T., Han, S. H., & Koh, K. K. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0624 · Cited by 39
Nutritional prevention of colorectal cancer
Hull, M. A. (2020) · Proceedings of The Nutrition Society · doi:10.1017/s0029665120000051 · Cited by 43
“The large (n 25 871) VITAL trial tested the effect of mixed marine n-3 PUFA (1 g daily including 460 mg EPA and 380mg DHA) on invasive cancer of any type in a 2 × 2 factorial trial with vitamin D3 (2000 IU daily)((25)).”
Zirpoli, H., Chang, C. L., Carpentier, Y., Michael-Titus, A. T., Ten, V. S., & Deckelbaum, R. J. (2020) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124539 · Cited by 40
“After a follow-up of over 5 years, groups receiving omega-3 FA supplements did not show a lower incidence in the primary end points of major cardiovascular events (a composite of MI, stroke, or death from cardiovascular causes) and invasive cancer of any type, compared with placebo groups (80).”
BackgroundDrenjančević, I., & Pitha, J. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042104 · Cited by 52
“VITAL [28] Vitamin D3 (2000 IU per day) and 1 g fish-oil capsule (EPA-460 mg, DHA-380 mg) vs.”
InfluentialPotential of Omega 3 Supplementation for Coronavirus Disease 2019 (COVID-19): A Scoping Review
Fadiyah, N. N., Megawati, G., & Luftimas, D. E. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s357460 · Cited by 40
Wang, Y., Fang, Y., Magliano, D. J., Charchar, F. J., Sobey, C. G., Drummond, G. R., & Golledge, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac124 · Cited by 39
Karbownik, M. S., Paul, E., Nowicka, M., Nowicka, Z., Kowalczyk, R. P., Kowalczyk, E., & Pietras, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218398 · Cited by 42
Metabolomics Biomarkers for Precision Psychiatry
Shih, P.-A. B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-21735-8_10 · Cited by 41
Song, M., Lee, I.-M. M., Manson, J. E., Buring, J. E., Dushkes, R., Gordon, D., Walter, J. N., Wu, K., Chan, A. T., Ogino, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4587 · Cited by 38
Self-citationDyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?
Lewek, J., & Banach, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01030-w · Cited by 40
Trim the fat: the role of omega-3 fatty acids in psychopharmacology
Nasir, M., & Bloch, M. H. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319869791 · Cited by 38
He, M., Tan, C. P., Xu, Y., & Liu, Y. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109812 · Cited by 37
The year in cardiology 2018: prevention
Reiner, Ž., Laufs, U., Cosentino, F., & Landmesser, U. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy894 · Cited by 37
Nagatake, T., Kishino, S., Urano, E., Murakami, H., Kitamura, N., Konishi, K., Ohno, H., Tiwari, P., Morimoto, S., Node, E., et al. (2022) · Mucosal Immunology · doi:10.1038/s41385-021-00477-5 · Cited by 38
Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
Malick, W. A., Waksman, O., Do, R., Köenig, W., Pradhan, A. D., Stroes, E. S. G., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.034 · Cited by 38
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 41
Metherel, A. H., Valenzuela, R., Klievik, B. J., Cisbani, G., Rotarescu, R. D., Gonzalez‐Soto, M., Cruciani‐Guglielmacci, C., Layé, S., Magnan, C., Mutch, D. M., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100548 · Cited by 42
“RCTs using mixed EPA/DHA supplements to reduce cardiovascular disease end points have been unsuccessful (61, 62) while two RCTs sup-plementing EPA alone reported cardiovascular benefits (63, 64).”
ResultRegular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study
Chen, G., Qian, Z. M., Zhang, J., Zhang, S., Zhang, Z., Vaughn, M. G., Aaron, H. E., Wang, C., Lip, G. Y. H., & Lin, H. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2022-000451 · Cited by 49
“10 All of these factors might preclude direct comparison of the effects of omega 3 fatty acids on atrial fibrillation events or on further deterioration of cardiovascular disease.”
BackgroundBioprospecting for Antithrombotic Polar Lipids from Salmon, Herring, and Boarfish By-Products
Τσούπρας, Α., O’Keeffe, E., Lordan, R., Redfern, S., & Zabetakis, I. (2019) · Foods · doi:10.3390/foods8090416 · Cited by 36
“Interestingly, the protective effects of ω3 fatty acids are more evident in patients with low fish consumption (as shown in the VITAL clinical trial (Vitamin D and Omega-3 Trial) [16]).”
BackgroundLiu, J., Li, X., Hou, J., Sun, J., Guo, N., & Wang, Z. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1779321 · Cited by 37
“And a recent randomized controlled trial (RCT) conducted by Manson (15) suggested that supplementation of n3 PUFAs did not lower the incidence of cancer compared to placebo.”
BackgroundInfluentialBanach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Santos, H. O., May, T. L., & Bueno, A. A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1107475 · Cited by 41
“A few studies have demonstrated that n-3 PUFA supplementation achieved by fish oil supplementation will not always significantly reduce the risk of major cardiovascular events, nor will it always be useful for the primary and secondary prevention of cardiovascular events, including all-cause mortality, cardiovascular…”
BackgroundSasaki, N., Jones, L., & Carpenter, D. O. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.12.007 · Cited by 36
Cardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33
Choi, G. Y., & Calder, P. C. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1423228 · Cited by 36
“This was an RCT conducted as a two-by-two factorial design of vitamin D3 (at a dose of 50 μ g/day) and EPA + DHA (1 g/day) among 25,871 healthy participants aged over 50 years for the primary prevention of CVD and cancer (79).”
MethodZhao, W., Hylton, N. K., Wang, J. P., Chindavong, P. S., Alural, B., Kurtser, I., Subramanian, A., Mazitschek, R., Perlis, R. H., & Haggarty, S. J. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.06.006 · Cited by 39
Labenz, C., Prochaska, J. H., Huber, Y., Nagel, M., Straub, B. K., Wild, P. S., Galle, P. R., & Schattenberg, J. M. (2019) · Hepatology Communications · doi:10.1002/hep4.1428 · Cited by 35
Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason, R. P., Sherratt, S. C. R., & Eckel, R. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101681 · Cited by 39
Bramante, C. T., Buse, J. B., Liebovitz, D., Nicklas, J. M., Puskarich, M. A., Cohen, K., Belani, H., Anderson, B., Huling, J. D., Tignanelli, C. J., et al. (2022) · medRxiv · doi:10.1101/2022.12.21.22283753 · Cited by 35
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34
Sekikawa, A. M., Cui, C., Sugiyama, D., Fabio, A., Harris, W. S., & Zhang, X. (2019) · Nutrients · doi:10.3390/nu11112599 · Cited by 38
Costenbader, K. H., MacFarlane, L. A., Lee, I.-M. M., Buring, J. E., Mora, S., Bubes, V. Y., Kotler, G., Camargo, C. A., Manson, J. E., & Cook, N. R. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.306902 · Cited by 34
Self-citationMayer, C., Richard, L., Côme, M., Ulmann, L., Nazih, H., Chénais, B., Ouguerram, K., & Mimouni, V. (2021) · Nutrients · doi:10.3390/nu13020430 · Cited by 39
Assessing vitamin D metabolism – four decades of experience
Herrmann, M. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1267 · Cited by 34
Omega-3 Fatty Acids in Arterial Hypertension: Is There Any Good News?
Brosolo, G., Porto, A. D., Marcante, S., Picci, A., Capilupi, F., Capilupi, P., Bertin, N., Vivarelli, C., Bulfone, L., Vacca, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119520 · Cited by 45
Foundational Nutrition: Implications for Human Health
Townsend, J. R., Kirby, T. O., Marshall, T. M., Church, D. D., Jajtner, A. R., & Esposito, R. (2023) · Nutrients · doi:10.3390/nu15132837 · Cited by 47
“Given the other reported benefits of omega-3 consumption on reductions in major adverse cardiovascular events [144], cancer development [145], Alzheimer’s and cognitive decline [146], depression [147], rheumatoid arthritis [148], and many other conditions [149], it is clear that these biological compounds are powerful…”
BackgroundStrategies to improve bioavailability of omega-3 fatty acids from ethyl ester concentrates
Maki, K. C., & Dicklin, M. R. (2018) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000537 · Cited by 35
Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence
Sherratt, S. C. R., Lero, M., & Mason, R. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000665 · Cited by 33
Differentiating EPA from EPA/DHA in cardiovascular risk reduction
Toth, P. P., Chapman, M. J., Parhofer, K. G., & Nelson, J. R. (2022) · American Heart Journal Plus: Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100148 · Cited by 33
“Findings from ASCEND (A Study of Cardiovascular Events in Diabetes) and VITAL (Vitamin D and Omega-3 Trial), which used low-dose ( ≤ 1 g) formulations, were consistent with earlier studies [26,27].”
ResultPolyphenol-Enriched Protein Oleogels as Potential Delivery Systems of Omega-3 Fatty Acids
Wang, G.-S., Chen, H., Feng, G., Yuan, Y., Wan, Z., Guo, J., Wang, J., & Yang, X. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06348 · Cited by 33
The regulatory role of dietary factors in skeletal muscle development, regeneration and function
Wang, L., Xu, Z., Ling, D., Li, J., Wang, Y., & Shan, T. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1828812 · Cited by 33
“…anticancer, anti-diabetes, improving depression and cognitive, and so on (Brown et al. 2019; Calder 2003, 2015; F et al. 2019; Flachs, Rossmeisl, and Kopecky 2014; Group et al. 2018; Johnson et al. 2008; Manson et al. 2019; Natto et al. 2019; Tomdio, Ritchie, and Miller 2019; Yang et al. 2019).”
BackgroundTherapeutic Potentials of Microalgae and Their Bioactive Compounds on Diabetes Mellitus
Tamel Selvan, K., Goon, J. A., Makpol, S., & Tan, J. K. (2023) · Marine Drugs · doi:10.3390/md21090462 · Cited by 32
Lombardi, M., Chiabrando, J. G., Vescovo, G. M., Bressi, E., Del Buono, M. G., Carbone, S., Koenig, R. A., Van Tassell, B. W., Abbate, A., Biondi-Zoccai, G., et al. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00865-5 · Cited by 33
Michaeloudes, C., Christodoulides, S., Christodoulou, P., Kyriakou, T.-C., Patrikios, I. S., & Stephanou, A. (2023) · Nutrients · doi:10.3390/nu15224830 · Cited by 38
“Antagonism between the two types of n -3 PUFAs, may explain the conflicting findings of large clinical studies on the effects of n -3 PUFAs on CVD risk factors [73–76].”
BackgroundBowman, G. L., Dodge, H. H., Guyonnet, S., Zhou, N., Donohue, J., Bichsel, A., Schmitt, J. A. J., Hooper, C., Bartfai, T., Andrieu, S., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.004 · Cited by 35
“These findings are consistent with several other nutritional interventions in older adults that targeted those with suboptimum nutritional status in primary [6] or secondary analyses [10] or determined a posteriori that baseline nutritional status dictated efficacy [2,3,8].”
ResultWang, Y., Han, S., Qin, H., Zheng, H., Jiang, B., Cao, Y., Gao, Y., Guan, L., Jia, Q., Jiang, Y., et al. (2020) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000385 · Cited by 32
Aldoori, J., Cockbain, A. J., Toogood, G. J., & Hull, M. A. (2022) · Gut · doi:10.1136/gutjnl-2021-326362 · Cited by 33
Li, J., Dou, K., Zhou, Z., Zhao, D. H., Ye, P., Zhao, J., & Guo, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1069992 · Cited by 37
Theinel, M. H., Nucci, M. P., Alves, A. H., Dias, O. F. M., Mamani, J. B., Garrigós, M. M., Oliveira, F. A., Rego, G. N. A., Valle, N. M. E., Cianciarullo, G., et al. (2023) · Nutrients · doi:10.3390/nu15061310 · Cited by 33
“Clinical studies reported the prevention effect ofω-3 PUFA intake in cancer and cardiovascular disease in adults more than 50 years old [24,64,75], and decreased latency was reported in preclinical studies [24].”
BackgroundEmerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
Wang, H., Yang, L., Wang, X., Cong, P., Xu, J., & Xue, C. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c07513 · Cited by 31
Okamura, T., Hashimoto, Y., Miki, A., Kaji, A., Sakai, R., Iwai, K., Osaka, T., Ushigome, E., Hamaguchi, M., Yamazaki, M., et al. (2020) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.19-85 · Cited by 35
Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review
Toth, P. P., Shah, P. K., & Lepor, N. E. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100086 · Cited by 35
Limonte, C. P., Zelnick, L. R., RUZINSKI, J. T., Hoofnagle, A. N., Thadhani, R., Melamed, M. L., Lee, I.-M. M., Buring, J. E., Sesso, H. D., Manson, J. E., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05300-7 · Cited by 31
“Our findings are consistent with the parent VITAL trial, which did not demonstrate a reduction in major cardiovascular events or invasive cancer with either intervention, though treatment with vitamin D showed a signal for reduction in cancer death and n-3 fatty acids were associated with decreased incidence of myocar…”
MethodResultSelf-citationCardiovascular effects of omega-3 fatty acids: Hope or hype?
Jo, S., Han, S. H., Kim, S., Eckel, R. H., & Koh, K. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.02.014 · Cited by 32
Yang, J., Zhang, X., Li, K., Zhou, Y., Hu, Y., Chen, X., Liang, S., & Jiang, L. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.03.018 · Cited by 31
Bischoff-Ferrari, H. A., Willett, W. C., Manson, J. E., Dawson-Hughes, B. F., Manz, M. G., Theiler, R., Braendle, K., Vellas, B. J., Rizzoli, R., Kressig, R. W., et al. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.852643 · Cited by 37
Self-citationCai, Y., Zhang, Y., Qu, Q., Xiong, R., Tang, H., & Huang, C. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c02248 · Cited by 31
Omega-3 fatty acids and individual variability in plasma triglyceride response: A mini-review
Rundblad, A., Sandoval, V., Holven, K. B., Ordovás, J. M., & Ulven, S. M. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102730 · Cited by 35
Evidence of adequacy of postpartum care for immigrant women.
Katz, D., & Gagnon, A. J. (2002) · PubMed · Cited by 30
Lu, J., Liu, R., Ren, H., Wang, S., Hu, C., Shi, Z., Li, M., Liu, W., Wan, Q., Su, Q., et al. (2024) · Med · doi:10.1016/j.medj.2024.07.024 · Cited by 34
Metadata
- Authors
- Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., D’Agostino, D., Friedenberg, G., Ridge, C., Bubes, V., Giovannucci, E. L., Willett, W. C., & Buring, J. E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (J.E.M., N.R.C., I-M.L., W.C., S.S.B., S.M., H.G., C.M.A., D.G., T.C., D.D., G.F., C.R., V.B., E.L.G., W.C.W., J.E.B.), and the Departments of Epidemiology (J.E.M., N.R.C., I.-M.L., W.C.W., J.E.B.) and Nutrition (E.L.G., W.C.W.), Harvard T.H. Chan School of Public Health — all in Boston.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 23-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6392053
- OpenAlex
- W2899720772
- Semantic Scholar
- bb3183c85d8686140abdf23d14174712153d2ed2
- Cited by
- 979
- References
- 94
- Citations by year
- 2026: 78 · 2025: 93 · 2024: 98 · 2023: 121 · 2022: 130 · 2021: 136 · 2020: 162 · 2019: 141
- FWCI
- 94.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R0 CA138962)
- National Cancer Institute
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
- Keywords
- omega-3 fatty acids, cardiovascular disease prevention, cancer prevention, primary prevention, cardiovascular events, myocardial infarction, stroke, cancer mortality, coronary revascularization, dietary supplementation, cardiovascular risk reduction, cancer risk reduction, older adults, Black participants, cancer risk factors
- MeSH terms
- Aged, Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms, Fatty Acids, Omega-3, Incidence, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
